Recent news on

AUA 2007 - Multiple Investigations in Basic and Translational ...  -  25 May 2007
UroToday,Anai and associates reported on the administration of liposomal doxorubicin particles in a mouse model of bladder cancer [ABST 882].

Low Levels of Common Enzyme Key to Resistance in Ewing’s Sarcoma  -  25 May 2007
PressZoom (press release),When cells with different levels of caspase-8 expression were treated with the chemotherapy drug doxorubicin, no differences in sensitivity to the drug were

Doxil/Velcade Combination Therapy Approved for Myeloma  -  May 22, 2007
Facts and Comparisons,The FDA has approved a new combination treatment, Doxil (doxorubicin liposomal) with Velcade (bortezomib), for myeloma in patients who have relapsed or have

CRGN: Begins Ph I/II Trial of Belinostat w/Doxorubicin for Soft ...  -  May 2, 2007
Therapeutics Daily (subscription) (press release),...and safety of intravenous belinostat (PXD101), an HDAC inhibitor, in combination with doxorubicin for the treatment of Soft Tissue Sarcomas (STS).

CuraGen And TopoTarget Initiate Phase I/II Clinical Trial Of ...  -  May 3, 2007
Medical News Today (press release),Patients will receive their standard chemotherapy of doxorubicin every 3 weeks to which belinostat will be added in a 5-day intravenous regimen.

Course Directors: Robert S. Mocharnuk, MD  -  May 3, 2007
Clinical Care Options (subscription),Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an

Low Levels of Common Enzyme Key to Resistance in Ewing's Sarcoma  -  May 23, 2007
PharmaLive.com (press release),When cells with different levels of caspase-8 expression were treated with the chemotherapy drug doxorubicin, no differences in sensitivity to the drug were

FDA approves VELCADE plus DOXIL combination for multiple myeloma  -  May 23, 2007
News-Medical.net,Ortho Biotech Products has announced the US Food and Drug Administration (FDA) has approved the use of DOXIL (doxorubicin HCl liposome injection) in

Ortho Biotech: extended Doxil approval unlikely to significantly ...  -  May 22, 2007
Pharmaceutical Business Review...'Content The FDA have approved the use of Ortho Biotech's Doxil (liposomal doxorubicin) in combination with Millennium Pharmaceuticals/Ortho Biotech's

Bacterially derived nanocells offer direct route for cancer therapy  -  May 16, 2007
BiopharmaReporter.com,For example, with delivery of minicells carrying doxorubicin or paclitaxel, tumour growth inhibition was significantly more marked in the xenograft models

Velcade Plus Doxil Approved For Myeloma Treatment  -  May 22, 2007
eMaxHealth.com,Doxil is a specially (liposomal) formulated version of the chemotherapy agent doxorubicin, and is approved for use in other forms of cancer.

Genitope Corporation Initiates Clinical Trial to Evaluate Use of ...  -  May 22, 2007
PipelineReview.com (press release),...to receive rituximab and chemotherapy (cyclosphosphamide, vincristine and prednisone either with or without doxorubicin) may be eligible for the study.

US FDA approves Velcade® + Doxil® combination  -  May 22, 2007
Prdomain Business Register (press release),LP, today announced the US Food and Drug Administration (FDA) has approved the use of DOXIL® (doxorubicin HCl liposome injection) in combination with

Approvals: Herceptin, Reyataz, and Peg-Intron  -  May 21, 2007
Medscape (subscription)...regimen containing doxorubicin, cyclophosphamide, and paclitaxel for the adjuvant treatment of HER2-overexpressing node-positive breast cancer.

US FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of ...  -  May 21, 2007
PR-Inside.com (Pressemitteilung),LP, today announced the US Food and Drug Administration (FDA) has approved the use of DOXIL(R) (doxorubicin HCl liposome injection) in combination with

Pixantrone Granted Fast Track Designation By FDA For Relapsed ...  -  May 8, 2007
Medical News Today (press release),This study will explore the potential cardiac safety benefits of pixantrone in chemotherapy naïve patients when compared directly to doxorubicin.

Pixantrone Granted Fast Track Designation by FDA for Relapsed ...  -  May 7, 2007
PharmaLive.com (press release),This study will explore the potential cardiac safety benefits of pixantrone in chemotherapy naïve patients when compared directly to doxorubicin.

Navarra spin-out signs drug deal to develop Hepatitis C treatment  -  May 4, 2007
Science Business (subscription),The Company is testing a library of products— carbohydrate derivatives of marketed chemotherapeutics and biologics, including doxorubicin, irinotecan,

Pro-Pharmaceuticals and Digna Biotech Sign Agreement to Apply ...  -  Apr 30, 2007
PharmaLive.com (press release),The Company is testing a library of products--carbohydrate derivatives of marketed chemotherapeutics and biologics, including doxorubicin, irinotecan,

Ambrilia Announces First Quarter 2007 Results and Provides Update ...  -  May 9, 2007
SYS-CON Media,Proof-of-concept was established with doxorubicin, a targeted liposomal formulation which showed convincing results in animal solid tumor models.

Rituxan Phase II Data in Patients with Relapsing-Remitting ...  -  May 2, 2007
PipelineReview.com (press release),CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens in previously untreated patients.

Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP ...  -  26 Apr 2007
PharmaLive.com (press release),We have successfully completed Phase I clinical studies on HyACT(TM) formulations of two other chemotherapy drugs, doxorubicin and 5- flurouracil.

Immunology: Pimp my antibody  -  26 Apr 2007
Nature.com (subscription),They linked it to the chemotherapy agent doxorubicin in order to target the drug exclusively to cancer cells 3 . The question now is how effective this and

INNOVIVE Pharmaceuticals Announces Preclinical Data from INNO-206 ...  -  Apr 19, 2007
PipelineReview.com (press release),Researchers found that INNO-206, a form of doxorubicin that attaches to circulating albumin and becomes activated once located at the tumor site,

Innovive Pharmaceuticals Announces Data from Oncology Drug ...  -  Apr 11, 2007
PharmaLive.com (press release),Additionally, preclinical data on INNO-206, a doxorubicin prodrug for the treatment of various cancers, will be presented. The meeting takes place April

Thallion Pharmaceuticals Inc. Hires Executive Vice-President ...  -  Apr 25, 2007
Web Services Journal,Like well known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from a nonpathogenic microorganism. However, unlike these drugs that were

Treatment may fuel cancer's spread  -  Apr 6, 2007
Washington Post,Tests in mice show that using the chemotherapy drug doxorubicin or radiation both raised levels of TGF-beta, which in turn helped breast cancer tumors

Use of TGF- ß Inhibitor Could Reduce Metastases  -  Apr 6, 2007
Medscape (subscription)The study was conducted in a murine model of metastatic breast cancer, in which ionizing radiation or treatment with doxorubicin caused an increase in

Taxane Use And Dose-Dense Scheduling May Benefit Patients With ...  -  Apr 14, 2007
Medical News Today (press release),Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

CANCER TWIST  -  Apr 6, 2007
New York Post,Using the chemotherapy drug doxorubicin or radiation in tests raised levels of TGF-beta, spreading breast cancer to the lung.

BioAlliance Pharma Announces Participation in Paris SmallCap Event ...  -  Apr 24, 2007
PharmaLive.com (press release),A Phase II/III trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicin Transdrug(R) nanoparticle delivery

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist ...  -  Apr 17, 2007
CNW Telbec (Communiqués de presse),More specifically, the authors reported on the antitumor activity of JMR-132 in MX-1 human experimental, doxorubicin-resistant breast cancers,

Redlands' young scientists showing promise  -  Apr 23, 2007
Redlands Daily Facts,Freeland worked with biology professor Lisa Olson over the summer to research the effectiveness of doxorubicin, a widely used chemotherapy drug that

Neoadjuvant Taxotere®, Navelbine® and Herceptin® Active for ...  -  Apr 4, 2007
Cancer Consultants (press release),All patients underwent surgery followed by adjuvant doxorubicin and cyclophosphamide. These authors reported that 94% of patients had a clinical response

Cell Therapeutics, Inc. (CTI) Files for Special Protocol ...  -  Apr 4, 2007
Drug Newswire (press release),This study will explore the potential cardiac safety benefits of pixantrone in chemotherapy naïve patients when compared directly to doxorubicin.

Targeting Tumors The Natural Way  -  Mar 29, 2007
Medical News Today (press release),In contrast, an established tumor-homing agent linked to the cell toxin doxorubicin destroyed cells even when they expressed very little integrin,

BTG signs agreement with Novacea and KuDOS for AQ4N  -  Apr 19, 2007
PharmaLive.com (press release),...potent cytotoxicity comparable to other marketed Topoisomerase II inhibitors such as Novantrone(r) (mitoxantrone) and Adriamycin(r) (doxorubicin).

Novacea Acquires Worldwide Development and Commercialization ...  -  Apr 19, 2007
SYS-CON Media,...exhibits potent cytotoxicity comparable to other marketed Topoisomerase II inhibitors such as Novantrone® (mitoxantrone) and Adriamycin® (doxorubicin).

TODAY ON PHARMALIVE.COM  -  Apr 19, 2007
PharmaLive.com (press release),...(Taxol(R)) and doxorubicin, can trigger reactionary angiogenesis with concomitant increased secretion from tumors of angiogenic factors, such as VEGF.

Novacea Acquires Worldwide Development and Commercialization ...  -  Apr 19, 2007
Genetic Engineering News (press release),...potent cytotoxicity comparable to other marketed Topoisomerase II inhibitors such as Novantrone(R) (mitoxantrone) and Adriamycin(R) (doxorubicin).

Pro-Pharmaceuticals Issues Corporate Update  -  Apr 17, 2007
PharmaLive.com (press release),...and pre-clinical studies in combination with leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(R)).

Pro-Pharmaceuticals Issues Corporate Update  -  Apr 17, 2007
Business Wire (press release),...and pre-clinical studies in combination with leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin ® ).

S. Colin Neill Nominated to Pro-Pharmaceuticals Board of Directors  -  Apr 16, 2007
Genetic Engineering News (press release),DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(R)).

S. Colin Neill Nominated to Pro-Pharmaceuticals Board of Directors  -  Apr 16, 2007
Business Wire (press release),DAVANAT ® , in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin ® ).

Common wood mould by-product may hold bone marrow cancer cure  -  Apr 16, 2007
DailyIndia.com,...to commonly-used anti-myeloma drugs including dexamethasone and doxorubicin -Reduce myeloma growth in mice, andRapidly accumulate in cancer cells.

Thallion Pharmaceuticals Inc. Announces Update of Recent FDA ...  -  Apr 13, 2007
Web Services Journal,Like well known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from a nonpathogenic microorganism. However, unlike these drugs that were

AEterna Zentaris To Present First In Vitro Data for PI3K ...  -  Apr 13, 2007
PR-Inside.com (Pressemitteilung),The abstract reviews results which demonstrate that GHRH antagonist, JMR-132, inhibits doxorubicin resistant in MX-1 human breast cancers and induces growth

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial ...  -  Apr 12, 2007
Medical News Today (press release),Doxorubicin and ifosfamide are the most commonly used chemotherapeutic agents in patients with advanced soft tissue sarcoma, but response rates are low and

Alpha-lipoic acid trial for chemotherapy-induced peripheral neuropathy  -  Apr 11, 2007
ScienceBlogsOne study with another anticancer drug, doxorubicin, suggests that combination with alpha-lipoic acid is antagonistic in leukemia cells except at very high

Treatment-induced Growth Factor Causes Cancer Progression  -  Apr 11, 2007
Medical News Today (press release),Radiation therapy and the chemotherapeutic agents doxorubicin and docetaxel all increased TGF-beta levels and accelerated metastasis, an effect that was

Study Shows Treatment May Cause Cancer to Spread  -  Apr 9, 2007
Associated Content,Radiation therapy and chemotherapeutic agents docetaxel and doxorubicin all increased TGF-beta levels as well as accelerated metastasis.

Cancer may spread with chemotherapy: Study  -  Apr 9, 2007
Earthtimes.orgThe team conducted various tests on mice including the chemotherapy drug doxorubicin and found that such a treatment saw a rise in the levels of TGF-beta,

TGF-beta inhibitors stop tumors spreading to new sites  -  Apr 8, 2007
News-Medical.net,Carlos Arteaga and colleagues show that treating mice with mammary tumors with either radiation or the chemotherapeutic drug doxorubicin increased the

Stopping Breast Cancer Tumors From Spreading  -  Apr 8, 2007
drkoop.com...researchers at Vanderbilt University in Nashville, Tenn., studied the effects of radiation and a chemotherapeutic drug called doxorubicin on mice.

Study finds treatment may fuel cancer's spread  -  Apr 5, 2007
Reuters.uk,Tests in mice show that using the chemotherapy drug doxorubicin or radiation both raised levels of TGF-beta, which in turn helped breast cancer tumours

Mixing Adjuvant Therapies Prolongs Early Breast Cancer Survival  -  Apr 4, 2007
Psychiatric Times,...methotrexate, and 5-fluorouracil (87%) or anthracycline-based regimens (11%), such as doxorubicin (Adriamycin) and cyclophosphamide.

Pro-Pharmaceuticals Announces Tampa General Hospital Dosing ...  -  Apr 4, 2007
PharmaLive.com (press release),The Company has been conducting clinical and pre-clinical studies with DAVANAT(R) in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin

Pro-Pharmaceuticals Announces Tampa General Hospital Dosing ...  -  Apr 4, 2007
Business Wire (press release),The Company has been conducting clinical and pre-clinical studies with DAVANAT ® in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin,

Pro-Pharmaceuticals Reports Fourth Quarter and Full Year 2006 ...  -  Apr 3, 2007
PharmaLive.com (press release),DAVANAT(r), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(r)).

Pipex Pharmaceuticals Announces Fourth Quarter and Year End 2006 ...  -  Apr 2, 2007
Genetic Engineering News (press release),Publication of results of preclinical studies demonstrating the ability of COPREXA(TM) to protect against doxorubicin-induced cardiotoxicity in the

Pipex Pharmaceuticals Announces Fourth Quarter and Year End 2006 ...  -  Apr 2, 2007
WM Experts (press release),Publication of results of preclinical studies demonstrating the ability of COPREXA™ to protect against doxorubicin-induced cardiotoxicity in the journal

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional